A recent study published in JAMA suggests that administering alteplase intravenously between 4.5 to 24 hours after the onset of acute ischemic stroke could significantly improve functional recovery in patients with perfusion imaging evidence of salvageable brain tissue, especially when thrombectomy was not initially performed. Conducted across 26 Chinese stroke centers from mid-2021 to mid-2024, the trial involved 372 patients who presented beyond the standard treatment window but displayed imaging patterns indicating viable tissue.
The results indicated that 40% of patients treated with alteplase achieved functional independence (modified Rankin Scale score of 0–1) at 90 days, compared to 26% in the control group, showing a statistically significant benefit (adjusted risk ratio 1.52; P = .004). Despite a higher rate of symptomatic intracranial hemorrhage in the treatment group (3.8% vs. 0.5%; adjusted risk ratio 7.34; P = .01), the overall mortality at 90 days was similar between the treated and control groups (11%).
These findings suggest that in appropriately selected patients identified through perfusion imaging, alteplase’s therapeutic benefits can extend well beyond the traditional time window, providing functional improvements even without endovascular interventions. However, the increased risk of bleeding underscores the importance of careful patient selection and monitoring. This research could potentially expand thrombolytic therapy in resource-constrained settings or for late-arriving patients, as long as salvageable tissue is confirmed through imaging.
The study’s findings have significant implications for stroke treatment, highlighting the potential to improve outcomes in select patients even when traditional treatment windows have elapsed. By leveraging perfusion imaging to identify salvageable brain tissue, alteplase could offer extended therapeutic benefits, emphasizing the importance of precise patient selection and monitoring to manage the associated risks effectively.
In conclusion, the study demonstrates that alteplase administration between 4.5 to 24 hours post-stroke onset, based on perfusion imaging, can lead to improved functional recovery in patients with salvageable brain tissue, offering a promising approach to enhance stroke management beyond the conventional treatment window. While the risk of intracranial hemorrhage is elevated, careful patient selection and monitoring can help mitigate this risk, potentially expanding the use of thrombolytic therapy in late-presenting patients and resource-limited settings.
Read more on medicaldialogues.in